The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions.
For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three primary areas, the first of which is strongly influenced by the latter two:
- market potential,
- epidemiology (including HIV/AIDS patient trends) and
- the current and emerging technologies in both diagnostics and therapeutics.
This in-depth strategic analysis of the worldwide HIV/AIDS market discusses the technologies available and emerging and discusses realistic and theoretical market potential and detailed epidimiological assessments for various geographic regions (many to the national level), including:
- Sub-Saharan Africa
- North Africa/Middle East
- South/Southeast Asia
- East Asia
- Latin America
- Eastern Europe/Central Asia
- Western/Central Europe
- North America
The report focuses on the policy aspects of HIV/AIDS, the options presented, the factors associated with strategic market development of HIV/AIDS diagnostics and therapeutics, and prospects for the future. The major strategic market effects of epidemiology, medical technology, and market potential analyses are discussed in detail. The trends in epidemiology and social/political attitudes towards HIV/AIDS, as well as their impacts on developing markets, are selected in conjunction with the growing interest in HIV/AIDS preventive medicine. These are presented to provide the most informative picture of potential market advances in this field.
Market analysis for this report is limited in the sense of projections, market shares, etc. Instead, it considers the various aspects of broad market development and estimates throughout the world. It looks at regions of the globe in terms of their existing theoretic and realist market potential. This is tempered by discussions of where and how these markets may develop and the factors influencing them. This report does not discuss in detail the individual products that may be marketed in each of these countries. Some mention is made of specific product types by way of example, but greater emphasis is placed on the product classes, in their generic sense, and their application to HIV/AIDS per se and its complications. The focus of the report is on the strategic factors associated with existing and future market potentials to provide pharmaceutical and diagnostics companies wishing to enter the field with a “field general’s” perspective.